BMSSC
VRTX icon

B. Metzler seel. Sohn & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228M Sell
511,036
-4,233
-0.8% -$1.97M 2.12% 12
2025
Q4 		$234M Buy
515,269
+199,847
+63% +$86.1M 2.04% 11
2025
Q3 		$124M Sell
315,422
-4,199
-1% -$1.75M 1.09% 22
2025
Q2 		$142M Buy
319,621
+5,278
+2% +$2.43M 1.36% 18
2025
Q1 		$152M Buy
314,343
+233,584
+289% +$109M 1.57% 18
2024
Q4 		$32.4M Buy
80,759
+40,766
+102% +$18.9M 0.33% 55
2024
Q3 		$18.6M Buy
39,993
+4,758
+14% +$2.29M 0.18% 75
2024
Q2 		$16.5M Buy
35,235
+19,699
+127% +$8.55M 0.16% 75
2024
Q1 		$6.5M Sell
15,536
-64
-0.4% -$27.1K 0.07% 141
2023
Q4 		$6.35M Sell
15,600
-586
-4% -$216K 0.08% 144
2023
Q3 		$5.63M Buy
16,186
+586
+4% +$205K 0.08% 142
2023
Q2 		$5.49M Sell
15,600
-2,373
-13% -$800K 0.07% 185
2023
Q1 		$5.66M Sell
17,973
-2,326
-11% -$698K 0.09% 138
2022
Q4 		$5.86M Sell
20,299
-3,695
-15% -$1.13M 0.1% 139
2022
Q3 		$6.95M Buy
23,994
+756
+3% +$218K 0.13% 118
2022
Q2 		$6.55M Sell
23,238
-148
-0.6% -$39.6K 0.11% 136
2022
Q1 		$6.1M Buy
23,386
+71
+0.3% +$16.9K 0.08% 159
2021
Q4 		$5.19M Buy
23,315
+3,852
+20% +$749K 0.07% 182
2021
Q3 		$3.53M Buy
19,463
+1,000
+5% +$195K 0.05% 220
2021
Q2 		$3.72M Buy
18,463
+517
+3% +$108K 0.06% 194
2021
Q1 		$3.86M Buy
17,946
+1,157
+7% +$254K 0.06% 189
2020
Q4 		$3.92M Buy
+16,789
New +$3.85M 0.07% 164

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

B. Metzler seel. Sohn & Co's VRTX Position: Q1 2026 in Review

B. Metzler seel. Sohn & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 0.82% in Q1 2026, selling an estimated $1.97M and leaving 511,036 shares worth $228M. The position accounts for 2.12% of the portfolio, ranked #12.

B. Metzler seel. Sohn & Co first reported a position in VRTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $234M in Q4 2025. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • B. Metzler seel. Sohn & Co held 511,036 shares of Vertex Pharmaceuticals worth $228M as of Q1 2026.
  • B. Metzler seel. Sohn & Co sold 4,233 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.97M.
  • Vertex Pharmaceuticals made up 2.12% of B. Metzler seel. Sohn & Co's portfolio in Q1 2026, its #12 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • B. Metzler seel. Sohn & Co's Vertex Pharmaceuticals position peaked at $234M in Q4 2025.
  • 1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2026, filed 8 May 2026.